glp-1/gip dual agonist and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports BioWorld

The drugmakers departing Chief Scientific Officer Mikael Dolsten said there were encouraging results for several versions of the drug and that we believe a once-daily formulation has the potential to have a competitive profile in the obesity pill market

Synaptic inputs from stroke-injured brain to grafted human stem cell-derived neurons activated by sensory stimuli

Age can cut into your L-carnitine stores (so can diabetes and genetic conditions)

This product is sold exclusively for in vitro laboratory research

Recent clinical evidence suggests that sulforaphane raises levels of the potent antioxidant glutathione in the plasma and brain